[{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"||NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TGF-beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Continent Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Beijing Continent Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Continent Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Continent Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Norwest Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Pirfenidone","moa":"||Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avalyn Pharma \/ Norwest Venture Partners","highestDevelopmentStatusID":"9","companyTruncated":"Avalyn Pharma \/ Norwest Venture Partners"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BBT-877","moa":"||Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Zhongshan Hospital","sponsor":"Beijing Continent Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TNF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shanghai Zhongshan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shanghai Zhongshan Hospital \/ Beijing Continent Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Zhongshan Hospital \/ Beijing Continent Pharmaceutical"},{"orgOrder":0,"company":"Fujian Medical University Union Hospital","sponsor":"Beijing Continent Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Fujian Medical University Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fujian Medical University Union Hospital \/ Beijing Continent Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Fujian Medical University Union Hospital \/ Beijing Continent Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TGF-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute for Health Research","sponsor":"Manchester University NHS Foundation Trust","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TGF-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National Institute for Health Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Institute for Health Research \/ Manchester University NHS Foundation Trust","highestDevelopmentStatusID":"8","companyTruncated":"National Institute for Health Research \/ Manchester University NHS Foundation Trust"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"Pirfenidone","moa":"||Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avalyn Pharma \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"9","companyTruncated":"Avalyn Pharma \/ Perceptive Xontogeny Venture Fund"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blade Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blade Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TGF-beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution for Inhalation","sponsorNew":"Avalyn Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution for Inhalation","sponsorNew":"Avalyn Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LTP001","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avalyn Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Avalyn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avalyn Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Avalyn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DWN12088","moa":"||Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HEC585","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sunshine Lake Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sunshine Lake Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TNF","graph1":"Undisclosed","graph2":"Phase I","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blade Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Blade Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TNF","graph1":"Undisclosed","graph2":"Phase I","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Shanghai ShouYan Clinical Development Co.,Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Overseas Pharma \/ Shanghai ShouYan Clinical Development Co.,Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Shanghai ShouYan Clinical Development Co.,Ltd."},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Shanghai ShouYan Clinical Development Co.,Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Overseas Pharma \/ Shanghai ShouYan Clinical Development Co.,Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Shanghai ShouYan Clinical Development Co.,Ltd."},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Overseas Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||IL-6 \/TNF-alpha receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Biotech Acquisition Company","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blade Therapeutics \/ Biotech Acquisition Company","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Biotech Acquisition Company"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blade Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gyre Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TGF-beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Gyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gyre Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gyre Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Veterans Medical Research Foundation","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | San Diego Veterans Healthcare System | University of California, San Diego | University of California, San Francisco | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TNF","graph1":"Nephrology","graph2":"Phase II","graph3":"Veterans Medical Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veterans Medical Research Foundation \/ National Institute of Diabetes and Digestive and Kidney Diseases | San Diego Veterans Healthcare System | University of California, San Diego | University of California, San Francisco | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Veterans Medical Research Foundation \/ National Institute of Diabetes and Digestive and Kidney Diseases | San Diego Veterans Healthcare System | University of California, San Diego | University of California, San Francisco | Genentech"},{"orgOrder":0,"company":"Pulmonary Research of Abingdon","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pulmonary Research of Abingdon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pulmonary Research of Abingdon \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Pulmonary Research of Abingdon \/ Genentech"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nerandomilast","moa":"||PDE4B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Zhou Chengzhi","sponsor":"Beijing Continent Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TNF","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Zhou Chengzhi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhou Chengzhi \/ Beijing Continent Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Zhou Chengzhi \/ Beijing Continent Pharmaceutical"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nerandomilast","moa":"||PDE4B","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Soroka University Medical Center","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"||TNF","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Soroka University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soroka University Medical Center \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"Soroka University Medical Center \/ F. Hoffmann-La Roche"}]

Find Clinical Drug Pipeline Developments & Deals for esbriet

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Pirfenidone is an orally administered small molecule approved for the treatment of IPF. It works by inhibiting TGF-β signaling and fibroblast proliferation.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 31, 2025

                          Lead Product(s) : Pirfenidone,Inapplicable

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Pirfenidone,Inapplicable

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Shanghai ShouYan Clinical Development Co.,Ltd.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Pirfenidone,Inapplicable

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 26, 2024

                          Lead Product(s) : Pirfenidone,Inapplicable

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Shanghai ShouYan Clinical Development Co.,Ltd.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : BBT-877 a novel autotoxin (ATX) inhibitor, small molecule drug candidate which is currently being evaluated for the treatment of idiopathic pulmonary fibrosis.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 29, 2024

                          Lead Product(s) : BBT-877,Pirfenidone

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : AP01 is a novel formulation of inhaled pirfenidone optimized to target the lungs in patients with progressive pulmonary fibrosis (PPF).

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 09, 2024

                          Lead Product(s) : Pirfenidone,Inapplicable

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 05, 2024

                          Lead Product(s) : Nerandomilast,Pirfenidone

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : AP01 (pirfenidone) is a small molecule shown to inhibit fibroblast differentiation and extracellular matrix (ECM) production. It is being investigated in adults with pulmonary fibrosis.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 04, 2023

                          Lead Product(s) : Pirfenidone,Inapplicable

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 06, 2023

                          Lead Product(s) : Nerandomilast,Nintedanib Esylate,Pirfenidone

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Avalyn will use the funds for the development of its portfolio of inhalation therapies for interstitial lung disease that improve upon currently approved medications, and advance lead clinical assets, AP01 (pirfenidone) and AP02 (nintedanib), into mid-st...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 27, 2023

                          Lead Product(s) : Pirfenidone,Inapplicable

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Perceptive Xontogeny Venture Fund

                          Deal Size : $175.0 million

                          Deal Type : Series C Financing

                          blank